headshot Armin Winands

Armin Winands

CEO

Armin Winands is a highly experienced, successful and well-regarded business leader. He has gained experience in the markets of genetic testing, biomarker discovery and clinical assay development since 2010 and has built expertise in building and leading international teams for over 20 years. Armin is a people and customer focused individual with strong history of managing highly engaged and results oriented teams.

headshot Jan Hellemans

Jan Hellemans

CTO, co-founder

Jan Hellemans is one of the founders of Biogazelle and has been CEO from 2007 to 2018. In 2014, he successfully established Biogazelle as one of the fastest growing Belgian technology companies. Jan has a master in Biotechnology, a PhD in Medical Sciences (Ghent University, Belgium) and over 15 years of experience in human genetics. He acquired extensive experience in next generation sequencing and genetic diagnostics from managing an academic core facility and introducing the corresponding wet and dry lab technology in a clinical diagnostics lab at Ghent University Hospital.

headshot Jo Vandesompele

Jo Vandesompele

CSO, co-founder

Jo Vandesompele has a Master of Science in Bio-engineering and a PhD in Medical Sciences. As Chief Scientific Officer, he is responsible for the scientific progress in the company. Jo also holds a professorship at Ghent University, studying non-coding RNA biology in cancer and developing nucleic acid quantification strategies. He is co-author of more than 200 peer-reviewed articles, together cited more than 30 000 times.



headshot Ariane De Ganck

Ariane De Ganck

business unit manager

Ariane De Ganck has a Master in Biomedical Sciences and obtained her PhD in Biomedical Sciences after doing 4 years of cancer research at the Department of Medical Protein Research at VIB-UGent. As project manager of RNA biomarker discovery projects at Biogazelle, Ariane has become an expert in the domain. As product manager, she introduced state-of-the art transcriptome profiling workflows to the company’s portfolio, focusing on clinically relevant samples. These same technologies are now the building blocks of Biogazelle’s business unit offering innovative RNA solutions, currently lead by her.